Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

The combination of durvalumab, tremelimumab, and chemotherapy in the first-line setting improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic non-small-cell lung cancer (mNSCLC), according to results of the phase III POSEIDON trial.

26 Oct 2021

Baricitinib prevents death in critically ill COVID-19 patients

The oral selective JAK1/2 inhibitor baricitinib significantly reduces the risk of death in critically ill COVID-19 patients who are on invasive mechanical ventilation (IMV) or ECMO*, when used in combination with standard care, according to the addendum study of the COV-BARRIER trial presented at IDWeek 2021.

26 Oct 2021

Everolimus helps fight recurrent thymic neuroendocrine neoplasia

Treatment with everolimus appears to have beneficial effects on recurrent thymic neuroendocrine neoplasia (NEN), particularly well-differentiated tumours, with patients having a low Ki-67 index more likely to have a better outcome with the drug, as shown in a small study.

26 Oct 2021

Therapeutic heparin may reduce death, bleeding risks in moderate COVID-19

Use of therapeutic heparin does not appear to significantly reduce the death, mechanical ventilation, or intensive care unit (ICU) admission in hospitalized patients with moderate COVID-19 and increased D-dimer levels, reveals a study. However, it is associated with a significantly lower chances of all-cause death and reduced risk of major bleeding.

26 Oct 2021

Outpatient dose-adjusted EPOCH for B-cell lymphoma proven safe, feasible

A recent study has shown the safety and feasibility of routine outpatient administration of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH), with a positive annual impact on margin amounting to $1,444,548 at a comprehensive cancer centre.

Survival comparable in erlotinib-treated patients with, without renal insufficiency

Overall survival (OS) is similar between patients with and without renal insufficiency who have been treated with erlotinib, reports a study. Progression-free survival (PFS) is about 6 months shorter in PFS patients with classical mutation relative to those with RI, albeit statistically nonsignificant.

Study pinpoints factors linked to HPV vaccine series completion among teens

Individual- and community-level factors, such as age and travel distance to the clinic, among others, exert influence on the completion of human papillomavirus two-dose vaccine series among adolescents, according to a study.

PRONOUNCE: Relative cardiovascular safety of GnRH antagonists vs agonists still unresolved

The gonadotropin-releasing hormone (GnRH) antagonist degarelix and the GnRH agonist leuprolide appear to be similar in terms of the rate of cardiovascular events in a cohort of patients with prostate cancer, according to the results of the PRONOUNCE trial.

Molnupiravir pill: A game-changer in COVID-19?

24 Oct 2021 bởi

The investigational oral antiviral pill molnupiravir significantly slashed the risk of hospitalization or death by half in nonhospitalized adults with mild-to-moderate COVID-19, according to interim data from the phase III MOVe-OUT trial.

Dose-capping chemoradiotherapy tied to higher recurrence in rectal cancer